Quantcast

Industry news that matters to you.  Learn more

GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)

LabCorp, a leading global life sciences company, and GENFIT, a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, have announced the signing of a licensing agreement between GENFIT and Covance, LabCorp’s drug development business. The agreement will expand access to an innovative non-alcoholic steatohepatitis (NASH) liver diagnostic test for the clinical research market.

Biodesix to Present Data on Blood Based Diagnostic Tests for Patients with Non-Small Cell Lung Cancer (NSCLC)

Biodesix, Inc., recently announced that its data on genomic and proteomic blood-based diagnostic assays will be presented at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. These blood-based diagnostic tests for patients with non-small cell lung cancer (NSCLC) are developed with a focus on results within 72 hours of the patient’s blood being drawn so that clinicians can make treatment decisions sooner. The data will be presented as three posters.

OncoCyte Announces Initial Data From Ongoing Clinical Study of Collagen Type X as a Marker and Potential Diagnostic for Breast Cancer and Other Types of Human Cancers

BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation recently announced initial data from a large, prospective clinical study that showed the potential of PanC-Dx™, OncoCyte’s non-invasive diagnostic technology based on its proprietary set of cancer markers, as a non-invasive, blood-based diagnostic test to screen for multiple types of human cancers, including breast cancer. The early data showed the utility of the protein Collagen Type X (COL10A1) in distinguishing patients with malignant breast lesions from those with negative findings. The clinical data was presented by Maria Prendes, PhD, Director of Manufacturing at OncoCyte, at the American Association for Cancer Research (AACR) Annual Meeting during a poster presentation from 8:00 AM -12:00 PM EDT on Monday, April 20, 2015.

MediSapiens Expanding Rapidly into Precision Medicine and Genomic Diagnostics

Earlier this year MediSapiens announced a joint venture with International Cancer Advocacy Network (ICAN) to develop and publish Remission Coach®, a web-based solution that addresses the urgency of cancer management.  This innovative solution provides cancer patients with a personalized platform for actively determine the most appropriate clinical trial for that patient’s disease and treatment history. Now MediSapiens announces collaboration with Genoscoper Laboratories, leading animal DNA diagnostics laboratory.

Caprion Announces Agreement To In-License Xpresys Lung From Indi For Canadian Commercialization

Caprion recently announced an exclusive agreement to in-license Xpresys Lung in Canada from Indi (Integrated Diagnostics®). Xpresys Lung is a breakthrough, molecular diagnostic blood test that assists with the management of indeterminate lung nodules. The clinical laboratory developed test is currently only available in the United States and provides physicians with objective information to identify nodules with a high probability of being benign – potentially reducing unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system.